Menin inhibitors are emerging as a promising therapeutic approach in acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as KMT2A-rearranged and NPM1-mutated AML. These inhibitors disrupt the leukemogenic signaling pathways that drive leukemia cell proliferation by blocking the actions of menin. They can help restore regular gene expression and halt the progression of AML.
In this podcast episode, you will hear updates on menin inhibitors in AML from the 6th International Workshop on Acute Leukemias (iwAL), which took place in Phoenix, AZ. Experts Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, delve into current data on the four menin inhibitors being investigated in AML. They then go on to discuss the development of resistance to this drug class and the potential value of these agents in the post-transplant setting
The post An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more! appeared first on VJHemOnc.
